Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis covers the month of April 2005, with the report dated April 21, 2005. The filing serves to disclose a specific corporate event regarding intellectual property litigation rather than providing periodic financial results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a legal procedural update and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The primary disclosure concerns the rescheduling of a patent trial date, as detailed in the attached press release.
Guidance, Outlook, and Risks
- Legal Contingency: The company issued a press release on April 20, 2005, concerning the rescheduling of a patent trial date.
- Management Commentary: No specific management commentary on financial outlook or operational strategy is included in this filing.
- Risks: The filing highlights a contingency related to ongoing patent litigation, though specific details of the risk impact are not elaborated in the cover text.
Key Facts for Investor Verification
- Verify the specific patent involved in the rescheduled trial mentioned in Exhibit 99.1.
- Confirm the new trial date and the reasons for the rescheduling.
- Assess the potential financial impact of the patent litigation outcome on Sanofi-Aventis's product portfolio.
- Note that this filing contains no financial data; refer to the most recent Form 20-F or quarterly reports for financial performance.